This study is focused on efficiency of various rifaximin-α regimens in order to optimize the treatment and preventive approaches for cirrhosis of the liver with minimal hepatic encephalopathy, as well as to predict the course of the disease and the risk of complications.
BAKULIN et al. (2024) studied this question.